Logo

Atugen Signs RNAi Deal with Aventis

Sep 13, 2004

NEW YORK, Sept. 13 (GenomeWeb News) - Atugen said today that it has formed a collaboration with Aventis to identify siRNA compounds that have potential for development as therapeutics.

 

Atugen said the deal would combine its proprietary siRNA technology, including its stabilized siRNA compounds and delivery vehicles, with Aventis' pharmacology expertise "to inhibit pharmacologically relevant targets."

 

Additional terms of the deal were not disclosed.

 

Breaking News
The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.